Category «Uncategorized»

SRT-1720

SRT-1720 diHCl CAY10559 CAS: 1001645-58-4 (di HCl) , 925434-55-5 (free base) 1001645-58-4 (HCl) Chemical Formula: C25H25Cl2N7OS Molecular Weight: 542.483 Elemental Analysis: C, 55.35; H, 4.65; Cl, 13.07; N, 18.07; O, 2.95; S, 5.91 SRT-1720 HCl, SRT-1720 hudrochloride; SRT1720; SRT-1720; SRT 1720; CAY10559; CAY-10559; CAY 10559; SIRT-1933; SIRT 1933; SIRT1933. N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide dihydrochloride Molecular FormulaC25H23N7OS Average mass469.561 Da SRT-1720, …

Ketorolac

Ketorolac Molecular FormulaC15H13NO3 Average mass255.269 Da 1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro- 413572 [Beilstein] 5-(Phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid 5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid 5-Benzoyl-2,3-dihydro-1H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid 74103-06-3 [RN] Ketorolac CAS Registry Number: 74103-06-3 CAS Name: 5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid Additional Names: 5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid Manufacturers’ Codes: RS-37619 Molecular Formula: C15H13NO3 Molecular Weight: 255.27 Percent Composition: C 70.58%, H 5.13%, N 5.49%, O 18.80% Literature References: Prostaglandin biosynthesis inhibitor. Prepn and separation of isomers: BE 856681; J. M. Muchowski, A. …

Cavosonstat (N-91115)

Cavosonstat (N-91115) CAS 1371587-51-7 C16H10ClNO3, 299.71 g/mol UNII-O2Z8Q22ZE4, O2Z8Q22ZE4, NCT02589236; N91115-2CF-05; SNO-6 3-chloro-4-(6-hydroxyquinolin-2-yl)benzoic acid Treatment of Chronic Obstructive Pulmonary Diseases (COPD), AND Cystic fibrosis, Nivalis Therapeutics, phase 2 The product was originated at Nivalis Therapeutics, which was acquired by Alpine Immune Sciences in 2017. In 2018, Alpine announced the sale and transfer of global rights to Laurel Venture Capital for further …

VX-659, Bamocaftor potassium

VX-659, BAMOCAFTOR N-(Benzenesulfonyl)-6-[3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]pyrazol-1-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carboxamide 3-Pyridinecarboxamide, N-(phenylsulfonyl)-6-[3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethyl-1-pyrrolidinyl]- N-(benzenesulfonyl)-6-[3-[2-[l-(trifluoromethyl)cyclopropyl]ethoxy]pyrazol-l-yl]-2-[(4S)-2,2,4-trimethylpyrrolidin-l-yl]pyridine-3-carboxamide CAS Number 2204245-48-5 UNII: 8C7XEW3K7S BAMOCAFTOR M. Wt 591.65 Formula C28H32F3N5O4S Bamocaftor potassium CAS 2204245-47-4 Molecular Formula C28 H31 F3 N5 O4 S . K Molecular Weight 629.735 VX-659 VX-659 potassium salt VY7D8MTV72 (UNII code) WHO 11167 3-Pyridinecarboxamide, N-(phenylsulfonyl)-6-[3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]-1H-pyrazol-1-yl]-2-[(4S)-2,2,4-trimethyl-1-pyrrolidinyl]-, potassium salt (1:1) Potassium (benzenesulfonyl)[6-(3-[2-[1-(trifluoromethyl)cyclopropyl]ethoxy]-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridine-3-carbonyl]azanide PHASE 2 CYSTIC FIBRIOSIS , VERTEX Cystic Fibrosis …

Ferric carboxymaltose , カルボキシマルトース第二鉄

Ferric carboxymaltose カルボキシマルトース第二鉄 CAS: 9007-72-1 Molecular Formula, C24H44FeO25– Molecular Weight, 788.43616 g/mol (2S,3S,4S,5R)-4-[(2R,3R,4R,5S,6R)-5-[(2R,3R,4R,5S,6R)-3,4-dihydroxy-6-(hydroxymethyl)-5-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,3,5,6-tetrahydroxyhexanoate;iron(3+);oxygen(2-);hydroxide;hydrate Iron dextri-maltose Iron(3+) hydroxide oxide poly-(1–4)-alpha-D-glucopyranosyl-(1–4)-D-gluconate hydrate Polynuclear iron (III)-hydroxide 4(R)-(poly-(1–4)-O-alpha-D-glucopyranosyl)-oxy-2(R),3(S),5(R),6-tetrahydroxy-hexanoate Poly[D-glucopyranosyl(1–4)]-D-gluconic acid complex of hydrated iron(III) oxide japan pmda approved, 2019/3/26, Ferinject Treatment of patients with iron deficiency anemia Hematinic, Supplement (iron) LAUNCHED, 2007, Vifor Pharma, Anemia, iron deficiency 1 Injectafer 2. Ferinject 3. Iron Dextri-maltose 4. Unii-6897gxd6oe 5. Vit 45 6. Vit-45 7. Ferric …

Peficitinib hydrobromide, ペフィシチニブ臭化水素酸塩

Peficitinib hydrobromide ペフィシチニブ臭化水素酸塩 ASP015K, Rheumatoid Arthritis 1H-Pyrrolo(2,3-b)pyridine-5-carboxamide, 4-((5-hydroxytricyclo(3.3.1.13,7)dec-2-yl)amino)-, hydrobromide (1:1), stereoisomer 4-{[(1R,2s,3S,5r)-5-Hydroxyadamantan-2-yl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide hydrobromide (1:1) 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-[[(1R,3S)-5-hydroxytricyclo[3.3.1.13,7]dec-2-yl]amino]-, hydrobromide (1:1) U55XHZ5X6P Formula C18H22N4O2. HBr CAS 1353219-05-2 HBR 944118-01-8 BASE Mol weight 407.3048 PMDA, 2019/3/26 JAPAN APPROVED, Smyraf Peficitinib hydrobromide is used in the treatment of Psoriasis and Rheumatoid Arthritis Peficitinib (formerly known as ASP015K) is a pyrrolo[2,3-b]pyridine derivative orally administered …

Cefamandole, セファマンドール ,цефамандол , سيفاماندول , 头孢孟多 ,

Cefamandole セファマンドール цефамандол [Russian] [INN] سيفاماندول [Arabic] [INN] 头孢孟多 [Chinese] [INN] CAS Registry Number: 34444-01-4 CAS Name: (6R,7R)-7-[[(2R)-Hydroxyphenylacetyl]amino]-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Additional Names: 7-mandelamido-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; 7-D-mandelamido-3-[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-3-cephem-4-carboxylic acid; 7-D-mandelamido-3-(1-methyl-1,2,3,4-tetrazole-5-thiomethyl)-D3-cephem-4-carboxylic acid; CMT Manufacturers’ Codes: compd 83405 Molecular Formula: C18H18N6O5S2 Molecular Weight: 462.50 Percent Composition: C 46.74%, H 3.92%, N 18.17%, O 17.30%, S 13.87% Literature References: Broad-spectrum semi-synthetic cephalosporin antibiotic. Prepn: C. W. Ryan, DE 2018600; idem, US3641021 (1970, 1972 to Lilly); J. M. Greene, DE 2312997; idem, US 3840531 (1973, 1974 to …

Tegaserod, テガセロド

Tegaserod Molecular FormulaC16H23N5O Average mass301.387 Da テガセロド 145158-71-0 cas HTF 919 / HTF-919 / SDZ HTF 919 / SDZ-HTF-919 N’-[(E)-[(5-methoxy-1H-indol-3-yl)methylidene]amino]-N-pentylguanidine (2E)-2-[(5-Methoxy-1H-indol-3-yl)methylene]-N-pentylhydrazinecarboximidamide [ACD/IUPAC Name] (2E)-2-[(5-methoxy-1H-indol-3-yl)methylidene]-N’-pentylhydrazinecarboximidamide (2E)-2-[(5-methoxy-1H-indol-3-yl)methylidene]-N-pentylhydrazinecarboximidamide 145158-71-0 [RN] 7606 Hydrazinecarboximidamide, 2-[(5-methoxy-1H-indol-3-yl)methylene]-N-pentyl-, (2E) Sundaram Venkataraman, Srinivasulu Gudipati, Brahmeshwararao Mandava Venkata Naga, Goverdhan Banda, Radhakrishna Singamsetty, “Process for preparing form I of tegaserod maleate.” U.S. Patent US20050272802, issued December 08, 2005.US20050272802 Tegaserod maleate [USAN] 189188-57-6 Tegaserod CAS …

BMS-986236

BMS-986236 CAS 2058035-15-5 MW C22 H25 N9 O MF 431.49 1-(5-(4-(3-Hydroxy-3-methylbutyl)-1H-1,2,3-triazol-1-yl)-4-(isopropylamino)pyridin-2-yl)-1H-pyrazolo[3,4-b]pyridine-5-carbonitrile 1H-Pyrazolo[3,4-b]pyridine-5-carbonitrile, 1-[5-[4-(3-hydroxy-3-methylbutyl)-1H-1,2,3-triazol-1-yl]-4-[(1-methylethyl)amino]-2-pyridinyl]- 1-[5-[4-(3-hydroxy-3-methylbutyl)triazol-1-yl]-4-(propan-2-ylamino)pyridin-2-yl]pyrazolo[3,4-b]pyridine-5-carbonitrile The present invention generally relates to heteroaryl substituted aminopyridine compounds useful as kinase inhibitors, including the modulation of IRAK-4. Provided herein are heteroaryl substituted aminopyridine compounds, compositions comprising such compounds, and methods of their use. The invention further pertains to pharmaceutical compositions containing at least …

TAK-981

TAK-981 C25 H28 Cl N5 O5 S2, 578.103 [(1R,2S,4R)-4-[(5-[4-[(1R)-7-Chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl)amino]-2-hydroxycyclopentyl]methyl sulfamate [(1R,2S,4R)-4-[[5-[4-[(1R)-7-Chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methyl-thiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxy-cyclopentyl]methyl sulfamate Sulfamic acid, [(1R,2S,4R)-4-[[5-[[4-[(1R)-7-chloro-1,2,3,4-tetrahydro-1-isoquinolinyl]-5-methyl-2-thienyl]carbonyl]-4-pyrimidinyl]amino]-2-hydroxycyclopentyl]methyl ester CAS 1858276-04-6 FREE CAS 1858279-63-6 HYDRATE MW 578.103 Originator Takeda Oncology Class Antineoplastics Mechanism of Action Small ubiquitin-related modifier protein inhibitors Phase I Lymphoma; Solid tumours 01 Oct 2018 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) and and Lymphoma (Refractory metastatic disease, Second-line therapy …